Sarepta Therapeutics saw its stock jump 25% on Wednesday, March 25, 2026, following the release of encouraging Phase 1/2 clinical data for two experimental RNA interference (RNAi) medicines: SRP-1001 and SRP-1003. These candidates were acquired through a $1 billion-plus deal with Arrowhead Pharmaceuticals in 2024.
Scientific Highlights and Clinical Results:
-
Mechanism of Action: Both therapies utilize small interfering RNA (siRNA) strands delivered into muscle tissue to target genetic abnormalities driving rare, muscle-wasting conditions.
-
SRP-1001 (for FSHD1): Designed to suppress the production of DUX4, a protein toxic to muscle cells. Analysts described the drug’s ability to knock down DUX4-related genes after a single dose as “impressive,” outperforming results seen from rival programs.
-
SRP-1003 (for Myotonic Dystrophy Type 1): While data remains more limited than SRP-1001, the study achieved high muscle concentrations and provided proof-of-concept that the treatment can successfully hit its genetic target without severe side effects.
Strategic Context: The positive data provides a much-needed win for Sarepta, which has struggled with setbacks in its gene therapy pipeline (Elevidys), significant layoffs, and the impending retirement of CEO Doug Ingram. The success of these siRNA candidates validates the 2024 licensing deal and positions the platform as a potential cornerstone for the company’s “long-term viability.”
Despite the enthusiasm, experts remain cautious regarding long-term safety, particularly with SRP-1003, as researchers monitor cardiac events recorded during the trial to ensure they are truly unrelated to the treatment.
Source: https://www.biopharmadive.com/news/sarepta-arrowhead-trial-data-muscular-dystrophy/815681/